Skip to Content

CAPItello-280 trial aims to confirm findings from ProCAID trial

At the recent ACSO-GU symposium, the design and study endpoints from the CAPItello-280 trial were presented. The trial-in-progress aims to confirm the findings made in the ProCAID study, investigating the effects and safety of adding capivasertib to docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer (CRPC).

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top